Loading clinical trials...
Loading clinical trials...
A Phase 2, Randomized, Double-Blind, Vehicle-Controlled, Parallel Group Multicenter Study to Evaluate the Safety and Efficacy of CLS001 Topical Gel Versus Vehicle Applied Once Daily for 12 Weeks to Female Subjects With Moderate to Severe Acne Vulgaris
Conditions
Interventions
Omiganan (CLS001) Topical Gel
Vehicle Topical Gel
Locations
29
United States
Mobile, Alabama, United States
Phoenix, Arizona, United States
Santa Ana, California, United States
Santa Monica, California, United States
Denver, Colorado, United States
Boca Raton, Florida, United States
Start Date
October 1, 2015
Primary Completion Date
August 1, 2016
Completion Date
August 1, 2016
Last Updated
March 27, 2017
NCT07205107
NCT05891795
NCT06501560
NCT03883269
NCT07469228
NCT07348978
Lead Sponsor
Maruho Co., Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions